Skin Cancer Treatment Market By Type (Melanoma, Non-Melanoma), By Therapy (Immunotherapy, Targeted Therapy, Chemotherapy), By Distribution Channel (Hospitals Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031
Skin cancer is common type of cancer caused due to sun’s harmful radiation. The abnormal pigmentation, collagenosis, skin wrinkling, and solar keratosis on sun-exposed skin are the signs associated with skin cancer. There are two types of skin cancers including melanoma and non-melanoma. There are two types of non-melanoma cancers which includes basal cell carcinoma and squamous cell carcinoma. Non-melanocytic skin cancer is the most prevalent type of skin cancer detected in people which affects over 2-3 million people worldwide. There are several medicated treatments available for skin cancer which includes targeted therapy, chemotherapy, and immunotherapy.
Increase in prevalence of non-melanoma and melanoma type of skin cancer across the globe, availability of various skin cancer treatments, and increased demand for skin cancer treatment are the factors that positively influence the skin cancer treatment market growth. For instance, according to the American Cancer Society, in 2020, 5.4 million people were diagnosed with basal and squamous skin cancer in the U.S. each year and there are 2,000 people die with same cancer. As per the same source, estimated number of people suffering from basal and squamous skin cancer in U.S. is 3.3 million. The most common type of skin cancer frequently observed in American people is basal cell cancer with 8 out of 10 people. Squamous cell cancer is less likely observed in American people. In addition, initiatives taken by governments for the management of skin cancer and key players involved in the manufacturing and development of the advanced therapies for the effective skin cancer treatment are the factor boost skin cancer treatment market. For instance, in 2020, Novartis AG announced COMBI-AD clinical trial for the products Tafinlar + Mekinist to treat stage III BRAF V600-mutated melanoma patients to provide surgery to provide efficient, long-term effect for those patients who have high risk of cancer recurrence. In addition, availability of hospital pharmacies and drugs, diagnostic centers and hospitals influence the market growth. However, side effects associated with use of chemotherapy and radiotherapy skin cancer treatment restrain the market growth. Rise in number of product approvals and emergence of advanced therapies for skin cancer treatment are opportunities for the market growth.
The global skin cancer treatment market is segmented on the basis of type, therapy, distribution channel, and region. By type, the market is classified into melanoma and non-melanoma. The non-melanoma segment is further segmented into basal cell carcinoma, squamous cell carcinoma, and others. By therapy, the market is classified into immunotherapy, targeted therapy, and chemotherapy. By distribution channel, it is classified into hospitals pharmacies, drug stores & retail pharmacies, and online providers. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global skin cancer treatment market are Amgen Inc, Bristol Myers Squibb Company, F. Hoffman–La-Roche Ltd, GlaxoSmithKline Plc., LEO Pharm A/S, Merck KGAA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals and, Sun Pharmaceutical Industries Ltd.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the skin cancer treatment market analysis from 2021 to 2031 to identify the prevailing skin cancer treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the skin cancer treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global skin cancer treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Distribution Channel
Hospitals Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
By Type
Melanoma
Non-Melanoma
Type
Basal Cell Carcinoma
Squamous Cell Carcinoma
Others
By Therapy
Immunotherapy
Targeted Therapy
Chemotherapy
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest Of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest Of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest Of LAMEA
Key Market Players
Amgen Inc.
Bristol-Myers Squibb
F. Hoffmann-La Roche
Glaxosmithkline plc
LEO Pharma
Merck KGaA
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
Sun Pharmaceutical Industries Ltd.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook